Eosinophilic Granulomatosis with Polyangiitis (EGPA) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Eosinophilic Granulomatosis with Polyangiitis (EGPA) – Comprehensive Guide

Eosinophilic Granulomatosis with Polyangiitis (EGPA) – A Patient‑Friendly Guide

Overview

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg‑Strauss syndrome, is a rare autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation is driven by an over‑production of eosinophils—a type of white blood cell that normally fights parasites and participates in allergic reactions. When eosinophils accumulate in tissues, they release toxins that damage blood‑vessel walls, leading to organ dysfunction.

  • Who it affects: Adults, typically between 30 and 60 years old. Women are slightly more often affected than men (≈55 % women).
  • Prevalence: Approximately 3 – 4 cases per 1 million people worldwide, making it one of the rarest systemic vasculitides.1
  • Geography: Occurs worldwide, with slightly higher reported rates in North America and Europe, likely reflecting differences in diagnostic awareness.

Symptoms

EGPA evolves in three overlapping phases, but many patients experience symptoms from more than one phase at the same time.

1. Allergic (Prodromal) Phase

  • Asthma: New‑onset or worsening asthma that is often severe and difficult to control.
  • Allergic rhinitis / sinusitis: Nasal congestion, sneezing, loss of smell.
  • Eyelid or skin itching: Sometimes accompanied by hives (urticaria).

2. Eosinophilic Phase

  • Peripheral blood eosinophilia: A blood count showing >1,500 eosinophils/µL.
  • Lung infiltrates: Cough, shortness of breath, or chest pain due to eosinophilic pneumonia.
  • Gastro‑intestinal symptoms: Abdominal pain, nausea, vomiting, or diarrhea.
  • Skin lesions: Tender red nodules (called “purpura”), palpable or “pencil‑thin” plaques.

3. Vasculitic Phase (Organ‑threatening)

  • Peripheral neuropathy: Burning, tingling, or weakness—classically “mononeuritis multiplex” affecting multiple nerves.
  • Kidney involvement: Hematuria, proteinuria, or reduced kidney function.
  • Cardiac disease: Myocarditis, pericarditis, heart failure, or arrhythmias—present in up to 50 % of patients and the leading cause of mortality.2
  • Gastro‑intestinal ischemia: Severe abdominal pain, bleeding, or perforation.
  • Eye involvement: Vision changes, retinal vasculitis.

Because symptoms can mimic asthma, allergies, or other vasculitides, EGPA is often diagnosed after a combination of clinical clues and laboratory findings.

Causes and Risk Factors

EGPA is considered an autoimmune disorder; the precise trigger is unknown, but several factors appear to increase risk.

  • Genetic predisposition: Certain HLA‑DRB4 alleles are associated with higher susceptibility.3
  • Environmental exposures: Inhaled allergens, occupational dust, and certain drugs (e.g., leukotriene inhibitors) have been reported anecdotally.
  • History of asthma or allergic disease: Over 80 % of EGPA patients have long‑standing asthma before vasculitis appears.
  • ANCA status: About 40 % of patients are positive for anti‑neutrophil cytoplasmic antibodies (MPO‑ANCA). ANCA‑positive disease often features more renal and peripheral‑nerve involvement, whereas ANCA‑negative disease tends toward cardiac complications.
  • Age & gender: Onset in the 30‑60 year range; slightly higher incidence in women.

Diagnosis

Because EGPA is rare and its presentation varies, a systematic approach is essential.

Clinical Criteria

The American College of Rheumatology (ACR) 1990 criteria remain widely used. A diagnosis is likely when ≥ 4 of the following are present:

  1. Asthma
  2. Eosinophilia >10 % of leukocytes or >1,500/µL
  3. Mononeuritis multiplex or peripheral neuropathy
  4. Transient pulmonary infiltrates
  5. Paranasal sinus abnormality
  6. Biopsy showing eosinophil‑rich granulomatous inflammation

Laboratory Tests

  • Complete blood count (CBC): Elevated eosinophils.
  • ANCA testing: MPO‑ANCA (p‑ANCA) in ~40 % of cases; negative ANCA does not rule out EGPA.
  • IgE level: Often markedly increased, reflecting allergic background.
  • Renal and liver panels: To assess organ involvement.
  • Erythrocyte sedimentation rate (ESR) / C‑reactive protein (CRP): Usually elevated, indicating systemic inflammation.

Imaging

  • Chest X‑ray or CT scan: Shows transient infiltrates, nodules, or pleural effusion.
  • Sinus CT: Mucosal thickening, polyps.
  • Cardiac MRI or echocardiogram: Detects myocarditis or pericardial effusion.

Biopsy

Definitive diagnosis often requires tissue sampling from affected skin, nerve, lung, or sinus. Histology typically reveals:

  • Eosinophil‑rich inflammatory infiltrate
  • Necrotizing vasculitis of small‑ to medium‑diameter vessels
  • Granuloma formation

Additional Evaluations

  • Electromyography (EMG) for neuropathy assessment
  • Urinalysis for renal involvement
  • Pulmonary function tests (PFTs) to quantify asthma severity

Treatment Options

Therapy aims to suppress the immune response, control eosinophils, and protect organ function. Treatment is tailored to disease severity (mild, moderate, severe) and ANCA status.

Induction Therapy (First‑line)

  • Corticosteroids: Prednisone 1 mg/kg/day (usually 40‑60 mg) tapered over 6‑12 months. Steroids control inflammation rapidly and are the backbone of therapy.
  • Immunosuppressive agents: Added for moderate‑to‑severe disease or when rapid steroid taper is needed.
    • Azathioprine (2‑3 mg/kg/day) – often used for maintenance after remission.
    • Methotrexate (15‑25 mg weekly) – alternative in patients without severe organ involvement.
    • Mycophenolate mofetil (2‑3 g/day) – useful for renal or pulmonary disease.
  • Biologic agents: For refractory or ANCA‑positive disease.
    • Rituximab (375 mg/m² weekly × 4) – depletes B‑cells; comparable to cyclophosphamide in vasculitis trials.4
    • Mepolizumab (300 mg subcutaneously every 4 weeks) – anti‑IL‑5 antibody that specifically reduces eosinophils; FDA‑approved for EGPA in 2020.5
  • Cyclophosphamide: 2 mg/kg/day orally or IV pulses (15 mg/kg) for life‑threatening organ involvement (e.g., cardiac, renal). Reserved for short courses due to toxicity.

Maintenance Therapy

After achieving remission (usually 3‑6 months), many patients stay on a lower‑dose steroid (≤ 5 mg/day) plus one of the steroid‑sparing agents (azathioprine, methotrexate, or mycophenolate) for 12‑24 months. Long‑term low‑dose steroids may be continued if disease flares recur upon taper.

Adjunctive Care

  • Asthma management: Inhaled corticosteroids, long‑acting β2‑agonists, leukotriene modifiers (use cautiously).
  • Antiplatelet or anticoagulation: If there is a high risk of thrombosis due to vascular injury.
  • Cardiac monitoring: Regular ECGs and echocardiograms.
  • Vaccinations: Influenza, pneumococcal, and COVID‑19 vaccines (preferably before initiating high‑dose immunosuppression).
  • Pain & neuropathy control: Gabapentin, duloxetine, or physical therapy.

Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA)

While EGPA is chronic, many patients achieve long‑term remission with proper treatment. Practical strategies for daily life include:

  • Medication adherence: Use a pill organizer, set alarms, and keep a medication journal to track side effects.
  • Regular follow‑up: Schedule visits every 3‑6 months, or sooner if new symptoms arise.
  • Monitor labs at home: If you have a home blood‑pressure cuff, keep readings; some clinics offer home INR or CRP kits for those on anticoagulants or biologics.
  • Asthma action plan: Keep rescue inhaler (short‑acting β‑agonist) on hand, and know when to increase inhaled steroids.
  • Skin care: Use fragrance‑free moisturizers; avoid harsh soaps that can trigger itching.
  • Physical activity: Low‑impact exercises (walking, swimming, yoga) improve cardiovascular health without over‑taxing joints.
  • Nutrition: A balanced diet rich in omega‑3 fatty acids (fatty fish, flaxseed) may modestly reduce inflammation; limit processed foods and excess sodium, especially if on steroids.
  • Stress management: Mindfulness, breathing exercises, and counseling help mitigate disease‑related anxiety.
  • Support networks: Connect with vasculitis patient groups (e.g., Vasculitis Foundation) for shared experiences and coping tips.

Prevention

Because EGPA’s exact trigger is unknown, primary prevention is limited. However, actions that may lower risk or severity include:

  • Prompt treatment of persistent asthma and allergic rhinitis—work with an allergist to identify and avoid triggers.
  • Avoid exposure to known respiratory irritants (smoke, silica dust, certain chemicals).
  • Maintain a healthy weight and regular exercise to keep the immune system balanced.
  • Discuss any new medications (especially leukotriene inhibitors) with your physician, as rare case reports link them to EGPA onset.
  • Stay up‑to‑date with vaccinations to prevent infections that could precipitate a flare.

Complications

If untreated or poorly controlled, EGPA can lead to serious, sometimes irreversible damage:

  • Cardiac complications: Myocarditis, heart failure, arrhythmias—account for ~25 % of mortality.6
  • Renal failure: Rapidly progressive glomerulonephritis may require dialysis.
  • Peripheral neuropathy: Persistent weakness or loss of sensation, affecting daily tasks.
  • Gastro‑intestinal perforation or severe bleeding.
  • Vision loss: Due to retinal vasculitis.
  • Infections: High‑dose steroids and immunosuppressants increase susceptibility to bacterial, fungal, and viral infections.
  • Osteoporosis & metabolic syndrome: Long‑term corticosteroid use can reduce bone density and raise blood sugar.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden chest pain, palpitations, or shortness of breath that does not improve with inhalers.
  • Severe abdominal pain with vomiting, especially if accompanied by blood in vomit or stool.
  • Rapidly worsening weakness or numbness, especially if it spreads to multiple limbs.
  • Sudden loss of vision or double vision.
  • Persistent high fever (> 38.5 °C / 101.3 °F) despite antibiotics.
  • Signs of stroke – facial droop, slurred speech, arm weakness.
  • Blood in urine or a sudden drop in urine output.
  • Severe swelling of the face, lips, or tongue (possible allergic reaction to medication).

References

  1. Centers for Disease Control and Prevention. Vasculitis overview. https://www.cdc.gov/vaccinesafety/concerns/vasculitis.html
  2. Mayo Clinic. Churg‑Strauss syndrome (Eosinophilic granulomatosis with polyangiitis). https://www.mayoclinic.org
  3. G. Kallenberg et al., “HLA‑DRB4 association with EGPA,” *Arthritis & Rheumatology*, 2012.PMCID: PMC5086452
  4. W. Jones et al., “Rituximab versus cyclophosphamide for ANCA‑associated vasculitis,” *NEJM*, 2010.doi:10.1056/NEJMoa0900189
  5. L. Wechsler et al., “Mepolizumab for EGPA,” *NEJM*, 2017.doi:10.1056/NEJMoa1803766
  6. Cleveland Clinic. Cardiac involvement in EGPA.https://my.clevelandclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References